|Bid||0.7300 x 0|
|Ask||0.7500 x 0|
|Day's Range||0.0000 - 0.0000|
|52 Week Range|
|Beta (5Y Monthly)||1.25|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Mar 08, 2016|
|1y Target Est||N/A|
Toronto, Ontario--(Newsfile Corp. - December 31, 2020) - Canntab Therapeutics Limited. (CSE: PILL) (OTCQB: CTABF) (FSE: TBF1) ("Canntab" or the "Company"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the closing of a non-brokered private placement (the "Offering") of secured convertible debentures of the Company ("Convertible Debentures"), pursuant to which the Company issued Convertible Debentures for gross proceeds of $1,575,000 (the "Convertible Debentures"). The ...
Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQB:CTABF) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for medical and therapeutic applications, is pleased to announce that it has completed its first delivery of two (2) of a total of five (5) SKU's ordered by MediPharm Labs Corp. (TSE:LABS.TO) (OTC:MEDIF). Further to Canntab's press release dated June 2, 2020, the Company confirms that the total purchase order is approximately $1.3 Million. Canntab intends to complete and deliver the entire order by the end of 2020.
QUÉBEC CITY, Nov. 28, 2020 /CNW Telbec/ - The most recent data on the evolution of COVID-19 in Québec show 1,480 new cases, bringing the total number of people infected to 139,643.